Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Delaware for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Delaware only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Delaware (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Maged Hosny (NPI 1326003351)

Field	Value
Entity Type	Individual
Organization	Maged Hosny
Address	260 Beiser Blvd Ste 201
City	Dover
State	DE
ZIP	19904
Taxonomy	Rheumatology Physician
NPI Enumerated	April 20, 2006

Payer Source	Total Paid
Medicare	$3.1M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the available data: total Medicare revenue is $3.1M and there is no Medicaid billing on file, indicating Medicare drives the entirety of recorded public-payer revenue for this NPI. Analysts should treat Medicare patterns as representative of the provider’s public business mix rather than a mixed Medicaid/Medicare practice.

Revenue is highly concentrated in a small set of biologic drug codes: the precomputed top three Medicare codes account for 64.6% of the provider’s Medicare revenue, with J0129 at $898.4K (28.5%), J0717 at $676.8K (21.5%), and J0897 at $462.2K (14.7%). This concentration identifies a handful of infusible/ injectable specialty drugs as the primary revenue drivers.

The CPT/HCPCS mix reflects an infusion- and biologics-focused rheumatology practice: high-revenue J‑codes such as J0129 (abatacept), J0717 (certolizumab pegol), J0897 (denosumab) and Q5104 (infliximab biosimilar) together with chemotherapy/infusion administration codes 96413, 96401, and 96415 indicate on‑site administration of specialty injectables and sustained infusion capacity. These procedure codes plus E/M codes imply the practice combines outpatient visits with a substantive infusion service line.

The provider’s competitive standing is strong for several specific therapies: J0129 and J0717 each rank in the 95th percentile (notably above typical national volume) while J0897 ranks in the 99th percentile and is labeled an "extreme outlier," and Q5104 ranks #2 nationally in the 99th percentile (extreme outlier). Together these ranks point to dominant, above‑average national volume for multiple biologic agents and biosimilars rather than a low-volume community practice for these products.

Office visit volume is also meaningful and appears to support the infusion workstream: 99213 generated $89.6K (1.4K claims) and ranks in the 99th percentile (extreme outlier), while 99204 and 99214 also appear on the list with above‑typical ranks. High E/M counts alongside infusion codes suggest sustained patient throughput and recurring follow‑up consistent with chronic rheumatologic care.

The presence of both branded infliximab (J1745) and a biosimilar infliximab (Q5104) on the top codes — with Q5104 at $342.3K and ranked #2 nationally (99th percentile, extreme outlier) — signals substantial use of biosimilar therapy in addition to branded products, which may reflect formulary choice, payer contracting, or clinic sourcing strategies. This mix has implications for cost of goods and payer negotiation dynamics.

The provider has an established billing tenure: NPI was enumerated 2006-04-20 (~20 years ago), consistent with a long-running practice that could support the infrastructure (staffing, infusion suite, payer relationships) required to generate high infusion volumes. Tenure strengthens the plausibility of sustained specialty drug administration at scale.

Concentration risk and operational sensitivity are notable: with a majority of Medicare revenue tied to a few high-cost injectable agents (top three codes = 64.6%), the provider’s topline is exposed to changes in drug pricing, biosimilar adoption, and Medicare reimbursement for J‑codes and infusion administration. The lack of Medicaid billing on file also implies limited exposure to Medicaid populations and potential vulnerability if Medicare reimbursement policy or access to these specialty drugs shifts.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

22 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	28,080	$30	$898.4K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	169,200	$1	$676.8K
J0897	Injection, denosumab, 1 mg	25,680	$20	$462.2K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	11,410	$30	$342.3K
J1602	Injection, golimumab, 1 mg, for intravenous use	27,330	$10	$273.3K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	4,270	$30	$106.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	970	$100	$98.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,360	$70	$89.6K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	870	$60	$50.5K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	380	$130	$48.1K

Showing 1–10 of 22

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 22 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Delaware Distribution

Maged Hosny — 7 of 22 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Delaware

Full comparison — all codes billed, vs. state median

22 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	1	10	11,030	$30	$432.5K
J0717	2	10	98,800	$1	$376.8K
Q5104	1	10	11,410	$30	$339.1K
J1602	2	10	21,050	$10	$238.8K
J1745	4	10	3,610	$30	$134.3K
J0897	4	60	3,360	$20	$132.9K
96413	2	30	280	$100	$36.6K
99214	371	1,830	150	$80	$25.5K
96401	5	30	110	$60	$18.4K
J7325	1	10	2,270	$10	$16.6K

Showing 1–10 of 22

Related Providers

Other providers that share a Tax Identification Number (TIN) with Maged Hosny, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rheumatology Center Of Delaware, LLC	DE	Rheumatology Physician	$0	$4.9M
Linda Ashley	DE	Nurse Practitioner	$21.9K	$0
Debra Lynch	DE	Gerontology Nurse Practitioner	$12.7K	$0

Nearby Providers

Other providers in the same ZIP code as Maged Hosny, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bayada Home Health Care, Inc.	DE	Home Health Agency	$0	$37.9M
At Home Infucare, LLC	DE	Home Health Agency	$0	$28.5M
Amazing Home Care Agency	DE	Home Health Agency	$0	$18.7M
Dedicated To Women Ob-gyn, P.A.	DE	Obstetrics & Gynecology Physician	$0	$11.1M
Help At Home Of Delaware, LLC	DE	In Home Supportive Care Agency	$0	$10.7M
A Center For Mental Wellness, Inc.	DE	Mental Health Counselor	$0	$9.9M
State Of Delaware	DE	Case Management Agency	$0	$9.2M
West Dover Dental, LLC	DE	Dentist	$0	$9M
Americare Home Solutions	DE	In Home Supportive Care Agency	$0	$8.4M
Vicdania Health Services LLC	DE	Home Health Agency	$0	$7.4M

Maged Hosny — Billing Profile & Reimbursement Data

Sign up for Maged Hosny — Billing Profile & Reimbursement Data policy alerts

Maged Hosny — Billing Profile & Reimbursement Data

Sign up for Maged Hosny — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References